PCMP-E10 Antibody

What is the PCMP-E10 antibody and what epitopes does it recognize?

The PCMP-E10 is a mouse monoclonal antibody (clone E10) that specifically targets matrix proteins 1 and 2 (M1/M2) of Influenza A viruses. It was generated using the M2 extracellular domain peptide-KLH conjugate as an immunogen. The antibody shows reactivity across various Influenza A strains and has been validated in MDCK cells infected with Influenza A strains including WSN and Mmut variants.

For researchers planning experiments:

• Host species: Mouse

• Isotype: IgG2a

• Target molecular weights: M1 (27.9 kDa) and M2 (11.3 kDa)

• Storage conditions: -20°C for optimal stability and activity retention

What experimental applications has PCMP-E10 been validated for?

The PCMP-E10 antibody has been validated for multiple research applications with specific recommended dilutions:

Research has confirmed its utility in detecting viral protein expression dynamics following infection, making it valuable for time-course studies of influenza infection models.

How should I optimize Western blot protocols when using PCMP-E10 for influenza protein detection?

When optimizing Western blot protocols with PCMP-E10 antibody, consider these research-based guidelines:

• Sample preparation: Harvest influenza-infected cells at appropriate time points post-infection (typically 6-24 hours) to capture optimal protein expression

• Loading controls: Include both infected and uninfected cells to demonstrate specificity

• Dilution testing: Begin with 1:500 dilution and adjust based on signal strength

• Blocking optimization: Use 5% non-fat dry milk or BSA in TBST; test both if background issues occur

• Detection systems: HRP-conjugated secondary antibodies with either chemiluminescence or fluorescent detection work effectively

• Expected bands: Look for M1 protein at approximately 27.9 kDa and M2 at 11.3 kDa

For high-sensitivity applications, consider using enhanced chemiluminescence substrates and longer exposure times if signal strength is insufficient at recommended antibody concentrations.

What controls should I include when validating experimental results using PCMP-E10 antibody?

Proper experimental controls are critical for antibody validation, especially given concerns about the "antibody characterization crisis" in research . For PCMP-E10, implement:

• Negative controls:

  • Uninfected cell lysates/tissues to demonstrate absence of non-specific binding

  • Secondary antibody-only controls to assess background

  • Isotype controls (mouse IgG2a) to identify Fc receptor binding

• Positive controls:

  • Well-characterized influenza A-infected samples (preferably from established strains like WSN)

  • Recombinant M1/M2 proteins when available

• Specificity controls:

  • RNA interference or CRISPR knockout models targeting M1/M2 expression

  • Peptide competition assays using the immunizing peptide

  • Cross-validation with alternative antibodies against the same targets

This multi-faceted control approach aligns with modern antibody validation guidelines and helps ensure reliable, reproducible results in your research .

How can PCMP-E10 be effectively employed in studies of influenza virus assembly and trafficking?

For advanced studies examining viral protein dynamics during influenza assembly:

• Dual immunofluorescence approaches:

  • Co-stain with PCMP-E10 and antibodies against other viral components (HA, NA, NP) to track co-localization during assembly

  • Use time-course imaging to monitor M1/M2 trafficking to assembly sites

• Subcellular fractionation studies:

  • Use PCMP-E10 in Western blots of membrane, cytosolic, and nuclear fractions to track M1/M2 distribution

  • Combine with density gradient centrifugation to isolate assembly intermediates

• Live-cell imaging applications:

  • Consider secondary labeling strategies (e.g., Fab fragments) for live-cell compatibility

  • Correlate M1/M2 localization with viral budding events using membrane markers

• Electron microscopy applications:

  • Use gold-conjugated secondary antibodies with PCMP-E10 for immunoelectron microscopy

  • Precisely localize M1/M2 proteins during virion formation

These approaches can provide insights into the temporal and spatial organization of viral components during the assembly process, particularly the critical roles of matrix proteins in virion structure.

How does PCMP-E10 antibody compare to other available antibodies targeting influenza matrix proteins?

When selecting between available antibodies for influenza matrix protein research:

• Epitope considerations:

  • PCMP-E10 targets epitopes on both M1 and M2 proteins

  • Other antibodies may target only M1 or specific domains within M1/M2

  • Epitope accessibility may differ in native versus denatured conditions

• Cross-reactivity profiles:

  • PCMP-E10 shows broad reactivity across Influenza A strains

  • Consider strain-specific antibodies for subtype-restricted studies

  • Some antibodies may cross-react with proteins from other virus families

• Application-specific performance:

  • Some antibodies perform better in certain applications (e.g., IP vs. IHC)

  • PCMP-E10 has demonstrated utility in multiple applications including WB and IF

  • Consider using complementary antibodies for confirmation of results

• Validation rigor:

  • Evaluate the extent of validation data available

  • Consider independent validation in your specific experimental system

This comparative approach enables selection of the most appropriate antibody for specific research questions while acknowledging that proper antibody characterization is crucial for experimental reproducibility .

What strategies can address non-specific binding or high background when using PCMP-E10 in immunofluorescence studies?

When encountering background issues with PCMP-E10 in immunofluorescence applications:

• Fixation optimization:

  • Test different fixatives (4% paraformaldehyde, methanol, acetone)

  • Certain fixatives may better preserve epitopes while reducing background

  • Consider dual fixation protocols for optimal results

• Blocking enhancements:

  • Increase blocking time (1-2 hours at room temperature)

  • Test alternative blocking agents (normal serum from host species of secondary antibody)

  • Add 0.1-0.3% Triton X-100 to improve antibody penetration and reduce non-specific binding

• Antibody incubation adjustments:

  • Increase antibody dilution incrementally (test 1:500, 1:1000, 1:2000)

  • Perform incubations at 4°C overnight rather than at room temperature

  • Add 0.05% Tween-20 to antibody dilution buffer

• Wash protocol optimization:

  • Increase wash duration and volume

  • Use PBS-T (PBS + 0.1% Tween-20) for more stringent washing

  • Incorporate additional wash steps between antibody incubations

• Autofluorescence reduction:

  • Pre-treat samples with 0.1% sodium borohydride or 50mM NH₄Cl

  • Include Sudan Black B (0.1% in 70% ethanol) post-staining to quench lipofuscin autofluorescence

These methodological refinements can significantly improve signal-to-noise ratio in immunofluorescence applications with PCMP-E10 .

How should researchers validate PCMP-E10 antibody specificity when studying novel influenza strains or variants?

When applying PCMP-E10 to novel influenza strains or variants, implement this systematic validation approach:

• Sequence analysis:

  • Perform in silico epitope conservation analysis across the target strain

  • Identify potential amino acid substitutions in M1/M2 that might affect binding

  • Consider generating recombinant M1/M2 proteins with strain-specific sequences for direct testing

• Dose-response testing:

  • Run titration experiments (Western blot or ELISA) with increasing viral loads

  • Confirm linear relationship between signal intensity and viral protein abundance

  • Compare response curves between reference strains and novel variants

• Knockout validation:

  • When possible, generate M1/M2 mutant strains via reverse genetics

  • Demonstrate loss of antibody signal in knockout/mutant samples

  • This approach provides definitive evidence of specificity as recommended in modern antibody validation guidelines

• Cross-validation:

  • Use orthogonal detection methods (PCR, mass spectrometry) to confirm target expression

  • Compare results with alternative antibodies targeting different M1/M2 epitopes

  • Implement peptide competition assays using strain-specific peptide sequences

• Functional correlation:

  • Correlate antibody signal with functional measures of viral replication

  • Time-course studies should show expected patterns of M1/M2 expression during infection cycle

This comprehensive validation strategy addresses the antibody characterization concerns highlighted in the scientific literature and ensures reliable results when working with novel viral strains .

How can PCMP-E10 be applied in studies examining host-pathogen interactions during influenza infection?

PCMP-E10 can provide valuable insights into host-pathogen interactions through:

• Co-immunoprecipitation applications:

  • Identify novel host proteins interacting with viral M1/M2

  • Perform reverse IP experiments followed by mass spectrometry

  • Map temporal changes in protein-protein interactions during infection progression

• FRET/BRET interaction studies:

  • Use PCMP-E10 in combination with fluorescently-tagged host proteins

  • Measure proximity/interactions between viral and cellular components

  • Quantify interaction dynamics in response to antiviral treatments

• Proximity ligation assays:

  • Combine PCMP-E10 with antibodies against host factors

  • Visualize protein interactions at specific subcellular locations

  • Quantify interaction events per cell using automated image analysis

• Correlative microscopy approaches:

  • Use PCMP-E10 immunofluorescence combined with electron microscopy

  • Map M1/M2 distribution relative to cellular ultrastructures

  • Document membrane remodeling events associated with viral assembly sites

These methodological approaches enable detailed mechanistic studies of how influenza matrix proteins interact with and manipulate host cellular machinery during infection.

What considerations are important when using PCMP-E10 for quantitative analyses of viral protein expression?

For rigorous quantitative analysis of viral protein expression using PCMP-E10:

• Standardization protocols:

  • Include recombinant protein standards at known concentrations when possible

  • Generate standard curves for each experimental batch

  • Normalize signal to appropriate housekeeping proteins for relative quantification

• Signal linearity assessment:

  • Confirm linear detection range for the antibody (typically 2-3 orders of magnitude)

  • Use serial dilutions of positive control samples to establish quantitative limits

  • Ensure measurements fall within the verified linear range

• Technical replication strategies:

  • Run technical triplicates for critical samples

  • Consider running the same samples on multiple blots/plates

  • Calculate coefficient of variation to assess measurement precision

• Image acquisition optimization:

  • For fluorescence-based detection, verify detector linearity and avoid saturation

  • Use identical exposure settings across all experimental groups

  • Implement background subtraction using validated algorithms

• Advanced quantification approaches:

  • Consider multiplex detection systems for simultaneous quantification of multiple targets

  • Implement digital image analysis with appropriate segmentation algorithms

  • Use open-source software (ImageJ/FIJI) with standardized macros for reproducible analysis

These methodological considerations help ensure that quantitative measurements of viral protein expression are accurate, reproducible, and scientifically rigorous .